

## Supplementary material

---

*Dziewierz A, Zabojszcz M, Natorska J, et al. Dapagliflozin reduces plasma concentration of plasminogen activator inhibitor-1 in patients with heart failure with preserved ejection fraction and type 2 diabetes. Pol Arch Intern Med. 2022; 132: 16383. doi:10.20452/pamw.16383*

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

### Supplementary Table S1. Baseline characteristics

Variable	Included patients (n=12)
Age, years, mean (SD)	63.5 (5.5)
Women, n (%)	2 (16.7%)
Diabetes duration, years, median (IQR)	4.5 (0.3, 9.3)
Obesity, n (%)*	8 (66.7%)
Diabetes mellitus, n (%)	12 (100.0%)
Arterial hypertension, n (%)	8 (66.7%)
Hyperlipidemia, n (%)	10 (83.3%)
Chronic kidney disease, n (%)	1 (8.3%)
Metformin use, n (%)	12 (100.0%)
Rosuvastatin use, n (%)	6 (50.0%)
Atorvastatin use, n (%)	4 (33.3%)
HbA <sub>1c</sub> , %, mean (SD)	8.0 (2.2)
Total cholesterol, mmol/l, mean (SD)	4.5 (1.2)
HDL-C, mmol/l, mean (SD)	1.1 (0.4)
LDL-C, mmol/l, mean (SD)	2.7 (0.9)
Triglycerides, mmol/l, mean (SD)	1.4 (0.6)

eGFR, mL/min/1.73 m<sup>2</sup>, mean (SD)

78.0 (10.3)

---

Abbreviations: eGFR, estimated glomerular filtration rate; HbA<sub>1C</sub>, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation

\* body mass index  $\geq 30$  kg/m<sup>2</sup>

**Supplementary Figure S1.** Changes in plasminogen activator inhibitor-1 (PAI-1, panel A, mean with standard deviation) and clot lysis time (CLT, panel B, median with interquartile range) during follow-up.

